Inverness 'Dismayed' at Biosite's 'Silence' on Its Acquisition Offer | GenomeWeb
NEW YORK (GenomeWeb News) — Biosite has not responded to Inverness Medical Innovations' unsolicited offer to buy the company for $90 a share, Inverness said today, although Biosite issued a statement last Thursday saying it had received the offer and was evaluating it.
 
Inverness’s offer came just a week after Biosite agreed to be acquired by Beckman Coulter for $85 a share, or around $1.55 billion.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.